Wo sind die Myriadisten? - 500 Beiträge pro Seite

[smallfish]

Keine News im Board, Kurs dümpelt.
Weiß jemand mehr? Wer ist noch drin?
Wie sind Eure Erwartungen? Vor dem
Urlaub raus oder einfach laufen lassen?
Und ... was sagt der Biotech-Kenner
Nummer 2 dazu? Etwa gerade keine Zeit
für Recherche?

Fragen über Fragen. Bin dankbar für jede Antwort.

Petri Heil

Smallfish

[nipples]

Hi, smallfish,
ich bin bei 82E rein, war nicht rechtzeitig flüssig, ich laß` sie erstmal laufen, ich glaube immernoch an das KZ 300E! Vielleicht kommst Du vom Urlaub zurück, und sie ist auf dem Weg Richtung Norden, da wäre es schade, wenn Du jetzt raus gegangen wärst, oder?
stay long, Nipples

[IWA Japan]

@smallfush: normale konsolidierung wie der SEktor auf alle Fääe behalten.
mögliche Handlungsweisen:
1. stop-loos Order aufgeben, gefährlich
2. Handy dabei
3. Aktinefilter fragen und wie er einfach nicht drum kümmern

[smallfish]

Danke, Jungs, bleibe Mitglied im Club.

Good trades

Smallfish

PS: Nipples, wie überaus beneidenswert,
bei 82 eingestiegen zu sein. Wäre ich Du,
würde ich vier Wochen nach Hawaii
fliegen und nicht wie ich zehn Tage nach
Malle (bin selber seit 172 dabei).

[Nummer2]

Danke, smallfish !
Richtig getippt, keine Zeit momentan. Bei Myriad wird sich wohl auch nicht viel tun in den nächsten Tagen. Warten wir auf News ...

Bye, Nummer2

PS: Petri Heil!

[nipples]

Was will ich auf Hawaii?
Hab hier in Germany alles, was ich brauch, gute Aktien, Meinen Schatz und meinen Hund!! Nur etwas flüssiger wäre ich gern, aber welche Aktie verkaufen, sind alle zu gut!
Also viel Spaß auf Malle??? wünsche ich Dir bis denn
Nipples

[money_max]

SALT LAKE CITY, Aug. 17 /PRNewswire/ -- Myriad Genetics, Inc.
(Nasdaq: MYGN) announced today that it plans to launch a predictive medicine
test for hereditary colon cancer and uterine cancer in September 2000. The
test, named COLARIS(TM), is used to assess an individual`s risk of colon
cancer based on the presence of a mutation in either of two genes. The same
mutations also substantially increase a woman`s risk of endometrial cancer.
"COLARIS(TM) is the third molecular diagnostic product utilizing Myriad`s
highly accurate, high-throughput, DNA sequencing platform," said Peter
Meldrum, President and Chief Executive Officer of Myriad Genetics, Inc. "The
new test will provide the same gold standard quality to researchers and
clinicians for colon and endometrial cancer that has previously been achieved
in breast and ovarian cancer with Myriad`s BRACAnalysis(R) test. Individuals
who receive a positive COLARIS(TM) test result have an 80% lifetime risk of
colon cancer, and women who test positive have a 40 to 60% risk of uterine
cancer. With such important healthcare implications, the wide availability of
the COLARIS(TM) test is expected to provide a major step forward in the care
of individuals at increased risk of these cancers."
The root word "laris" in COLARIS(TM) was derived from lares, the ancient
Roman deities who were known as guardian spirits and protectors of one`s
ancestors. Protection against cancer is the goal of the COLARIS(TM) molecular
diagnostic test. Patients identified at high risk, following a positive
COLARIS(TM) test, will be placed on a regular schedule of office visits to
check for early signs of disease. This process of frequent surveillance along
with polyp removal can actually prevent colon cancers. Additionally,
chemoprevention approaches and certain dietary regimens hold promise in
reducing colon cancer risk, and studies with drugs such as NSAIDS and COX-2
inhibitors are determining the effectiveness of these drugs in preventing
colon cancer.
Myriad will begin accepting samples for testing nationwide in September.
The COLARIS(TM) molecular diagnostic test will be sold in the United States by
Myriad`s existing 40 person oncology product sales force. Worldwide product
rollout of the COLARIS(TM) molecular diagnostic test will follow introduction
in the United States.
Myriad Genetics, Inc. is an emerging biopharmaceutical company focused on
the development of therapeutic and diagnostic products that are based on the
use of genomic and proteomic technologies. The Company has established two
wholly owned subsidiaries -- Myriad Pharmaceuticals, Inc., which develops and
intends to market therapeutic compounds, and Myriad Genetic Laboratories,
Inc., which develops and markets proprietary molecular diagnostic services and
has introduced products in the fields of predictive medicine and personalized
medicine. The Company has established strategic alliances with Bayer, Eli
Lilly, Hitachi, Novartis, Pharmacia, Roche, Schering AG and Schering-Plough.
Note to Editors: This and other recent releases are available on Myriad`s
Web site at http://www.myriad.com.

The discussion in this news release includes forward-looking statements
that are subject to certain risks and uncertainties, including statements
regarding the launch date of Colaris, the effectiveness and quality of
Colaris, and its impact on the overall prevention and treatment of colorectal
cancers. Such statements are based on management`s current expectations that
are subject to risks and uncertainties that could cause actual results to
differ materially from those set forth or implied by forward-looking
statements, including, but not limited to, intense competition related to the
discovery of disease-related genes; uncertainties as to the extent of future
government regulation of the Company`s business, uncertainties as to whether
the Company and its collaborators will be successful in developing, and
obtaining regulatory approval for, and commercial acceptance of, therapeutics
based on the discovery of disease-related genes and proteins; uncertainties as
to the Company`s ability to develop therapeutic lead compounds, which is a new
business area for the Company; the risk that markets will not exist for
therapeutic lead compounds that the Company develops or if such markets exist,
that the Company will not be able to sell compounds, which it develops, at
acceptable prices.



SOURCE Myriad Genetics, Inc.

Schade, daß ich keine MYGN habe

[THIOUX]

Oncology (Nasdaq: GZMO) today announced it has licensed to Myriad Genetics, Inc.
(Nasdaq: MYGN) non-exclusive access to its cancer diagnostic patent rights
related to an undisclosed gene implicated in hereditary colon cancer.
In September 2000, Myriad plans to launch a predictive medicine test for
hereditary colon cancer called COLARIS(TM) that detects mutations in this gene
and an additional gene that is not part of the license agreement. Mutations in
either gene, in conjunction with a family history of colon cancer, indicate
increased risk for developing the disease. Additionally, the same mutations also
substantially increase a woman`s risk of endometrial cancer.
Under the license agreement, Genzyme Molecular Oncology received from Myriad an
up-front payment and will receive royalties on each COLARIS test performed.
Further financial details were not disclosed.
"This agreement is evidence of the continued value of Genzyme Molecular
Oncology`s intellectual property in expanding our diagnostic licensee base,
which already includes Affymetrix, LabCorp, and EXACT Laboratories," said Gail
Maderis, president, Genzyme Molecular Oncology. "As additional data from the
Human Genome Project is analyzed and as more molecular therapeutics reach
clinical and commercial development, we expect the interest in cancer
diagnostics to continue to grow."
Myriad has stated that its COLARIS test will provide the same high standard
quality to researchers and clinicians for colon and endometrial cancer that has
previously been achieved in breast and ovarian cancer with Myriad`s
BRACAnalysis(R) test. Myriad has announced that it will begin accepting samples
for testing with COLARIS nationwide next month.
Genzyme Molecular Oncology has an extensive portfolio of intellectual property
related to cancer gene diagnostics based on the work of its collaborators, Drs.
Kenneth Kinzler and Bert Vogelstein at The Johns Hopkins University. Genzyme
Molecular Oncology is out-licensing its diagnostic rights to generate funds to
help support its internal cancer therapeutic development efforts.
According to the American Cancer Society, colon cancer is the leading cause of
cancer death among non-smoking men and women in the United States, with 130,000
new cases and 56,000 deaths projected annually. Approximately 25 percent of all
colon cancer cases are triggered by a genetic predisposition to the disease.
Early detection of colon cancer or colon cancer risk offers physicians and
patients a significant advantage in the management and treatment of the disease.
Physicians can prescribe subsequent testing of family members, early colon
cancer surveillance, detection and removal of polyps, and in some cases
prophylactic surgery to help manage the disease. As medicine advances, more
drugs are also becoming available to treat colon cancer.
Genzyme Molecular Oncology is developing a new generation of cancer products
focusing on cancer vaccines and angiogenesis inhibitors. It is shaping these new
therapies through the integration of its genomics, gene and cell therapy,
small-molecule drug discovery, and protein therapeutic capabilities.
A division of Genzyme Corporation, Genzyme Molecular Oncology has its own common
stock intended to reflect its economic value and track its performance.
This press release contains forward-looking statements regarding the timing of
the launch of COLARIS, the receipt by Genzyme Molecular Oncology of royalties
from Myriad, the growth of cancer diagnostic testing, and the number of colon
cancer cases and deaths. Actual results may differ materially based on a number
of factors, including the actual timing of product launch, the actual sales of
COLARIS by Myriad, the results of the analysis of the Human Genome Project data,
the results of preclinical and clinical development of molecular therapeutics,
and the actual number of colon cancer cases and deaths. Further, because GZMO
stock is a series of common stock of Genzyme Corporation, GZMO shareholders are
subject to the risks and uncertainties described in reports filed by Genzyme
with the SEC under the Securities Exchange Act of 1934, as amended, including
without limitation Exhibit 99.2 to Genzyme`s 1999 Annual Report on Form 10-K.

[THIOUX]

MYRIAD RECEIVES $22M: Myriad Genetics Inc., a Salt Lake City gene-discovery
company, has received $22 million from Acqua Wellington North America Equities
Fund Ltd.
Acqua Wellington, part of a family of funds that targets investments in small-
and mid-cap companies, will receive 175,000 shares of Myriad common stock
slightly below market price.
Myriad, which has alliances with Bayer, Eli Lilly, Roche and other
pharmaceutical companies, will use the funding for research.
Founded in 1991, the company employs approximately 285 people. It recently
announced a two-for-one stock split and reported fiscal year 2000 losses of $8.7
million, down from $10 million in 1999. Revenue increased 34 percent in the year
ended June 30.

[positiva]

Bin vor 3 Wochen eingestiegen und seitdem fällt Myriad langsam runter - zumindest bis gestern. Werde abwarten und Tee trinken. Oder was meinen die Experten ?

[mahatma]

mein blue chip kommt in wallung
yyyyyyeeeeeeeeeeeeeeee yyyyyyeeeeeeeeeeeeeeeppppppppppp oder so ???!!!!


die woche ist gerettet
(schaut euch die indikatoren an = super geil )

gruß an alle mygn`s ler
maha

[THIOUX]

(Nasdaq: MYGN) announced today that its ProNet(R) technology will be used in the
massive scientific undertaking to discover the means by which cells communicate,
conducted by the Alliance for Cellular Signaling (AFCS). Knowledge of cell
signaling is essential to the development of new post-genomic era drugs that can
block the key communication lines that lead to disease. ProNet will be used to
discover the protein interactions within the cell and together with the
collected research of the consortium, will create a "virtual cell". This virtual
cell would function as a drug discovery generator, rapidly testing new drug
molecules against an accurate representation of a cell in a controlled but
dynamic experimental environment.
The AFCS is a consortium of 50 scientists from 20 Universities, led by Dr.
Alfred Gilman, Chairman of Pharmacology at UT Southwestern Medical Center at
Dallas, and scientists from Myriad Genetics and one other biotechnology company.
Researchers will work from five core laboratories and share data over a new
broadband Internet. The Alliance has received a $5 million grant from the
National Institute of General Medical Sciences (NIGMS), a division of the
National Institutes of Health. The NIGMS anticipates spending a projected total
of $25 million on the project over five years. In addition to the NIGMS grant,
the Alliance is receiving funding from pharmaceutical companies and research
institutions including Aventis, Chiron Therapeutics, Eli Lilly and Co., Johnson
& Johnson, Merck Genome Research Institute, Novartis, and the Agouron Institute.
"We are pleased to apply our proprietary ProNet(R) technology to this
prestigious and important effort to solve one of the largest remaining
far-reaching paradigms in biomedicine," said Dr. Paul Bartel, Vice President and
Head of ProNet for Myriad Genetics, Inc. "This model of building virtual cells
will greatly advance the fields of medical cardiology and immunology initially
and will become increasingly important as a means to create very targeted,
specific drugs for the treatment of many human diseases."
"The discovery of a cell`s protein-protein interactions is an enabling
technology, underlying the ability to understand cell signaling," said Dr.
Melvin Simon, Biaggini Professor of Biology and Chairman of Biology at
California Institute of Technology. "Myriad was chosen to participate in this
alliance due to its preeminent position in the proteomics field and its ability
to make a major impact on our understanding of the ways in which cells signal
one another."
ProNet is Myriad`s proprietary protein interaction technology, based upon a
highly automated, high-throughput form of the yeast two-hybrid system. ProNet
provides the means to identify proteins that interact to carry out cellular
processes. It can be applied to discover a single important disease pathway or
all of the protein control mechanisms within an entire cell, or even the entire
human protein complement.

[nobes]

Biotechnologie-Aktien erstmals eingestuft

Das Analystenhaus Dain Rauscher Wessels hat heute einige Biotechnologieaktien zum ersten mal einem Rating unterzogen:

Human Genomics Sciences (Nasdaq: HGSI) “Buy” Kursziel: 210 US-Dollar

CuraGen (Nasdaq: CRGN) “Buy “ Kursziel: 59 US-Dollar

Genencor International (Nasdaq: GCOR) “Strong Buy” Kursziel: 52 US- Dollar

Myriad Genetics (Nasdaq: MYGN) “Strong Buy” Kursziel: 225 US-Dollar

Celera Genomics Group (Nyse: CRA) “Buy” Kursziel: 151 US-Dollar

Gene Logic (Nasdaq: GLGC) “Buy” Kursziel: 40 US-Dollar

Incyte Genomics (Nasdaq: INCY) "Buy" Kursziel: 63 US-Dollar

Affymetrix (Nasdaq: AFFX) “Buy” Kursziel: 112 US-Dollar


Nobes

[kfb]

Hallo,weis jemand was mit MYGN los ist,habe heute keine erklärung für diesen Kurseinbruch!

[jxs]

Hi,

zum Thema Splitt: Übersetze ich das richtig? das nur diejenigen 2:1 teilnehmen die Myriad am 28.08. halten! Was ist wenn ich morgen kaufe.
Danke für die Antwort. jxs

SALT LAKE CITY, Aug. 16 /PRNewswire/ -- Myriad Genetics, Inc. (Nasdaq: MYGN) announced today that its Board of Directors has approved a two-for-one stock split of its Common Stock, effected in the form of a stock dividend of one new share for each share of Common Stock outstanding.

The stock dividend is payable on September 11, 2000 to stockholders of record at the close of business on August 28, 2000. As a result of the stock split, the number of outstanding shares of the Company`s Common Stock will increase to approximately 22,000,000.

[Svenöff]

Hi jxs,
soviel ich aus dem Schreiben meiner Bank entnehmen konnte,
ist bei Myriad ein 1:1 Splitt vorgesehen,
daß heist, denke ich, daß man für eine Aktie, die man im Depot hat,
eine dazubekommt (Kurshalbierung dann von z.B. 180 USD auf 90 USD).
Bei einem 2:1 Splitt würde man meiner Meinung nach, nach dem Splitt nicht mehr z.B. 20 Myriad sondern 60 Myriad besitzen, das hieße der Kurs müßte gedrittelt sein (z.B. von 180 USD auf 60 USD).
Wegen des 28.August: Bin der Meinung, daß du auf alle Fälle auch berücksichtigt wirst.Kann ja anders fast nicht sein,oder??
Was sollst du mit einem Myriad-Kauf-Kurs von 150 Euro, wenn die anderen, die schon investiert sind einen splittbereinigten Kaufkurs von 75 Euro (bei 1:1 Splitt) haben. Würdest du die Aktien wieder verkaufen wollen, müßtest du einen Verlust von 50% hinnehmen.
Für mich sehr schwer vorstellbar.
Kann vielleicht sein, daß deine neuen Aktien erst später in dein Depot eingebucht werden, als dies bei Anlegern der Fall ist, die den Wert bereits am 28.8. schon hatten.
Frag´aber lieber noch mal deine Bank,die müßt´s ja eigentlich wissen.
Bitte um Info, falls ich mit meiner Meinung total danebenliege.
Danke bereits im Voraus.
Grüße
Svenöff

[smallfish]

Moin zusammen!

Tappe auch völllig im Dunkeln, was den
Kurseinbruch von gestern abend anbelangt.
Würde mich ja nicht weiter beunruhigen, wenn
nicht der Biotech-Index so hoch im Plus
gewesen wäre.

Dennoch: Positive Meldungen kommen von der
Produktfront, Kaufempfehlungen häufen sich,
Splitt steht an. Kann doch eigentlich nur nach
Norden gehen (wo ich schließlich auch herkomme).

Tschüß

Smallfish

[boerse-bild]

Wie seht Ihr den weiteren Verlauf der Aktie?
Da entsteht doch gerade ein bullisches Dreieck, oder?